8-K: Profusa Announces Q2 2026 Results, G3 Vision Labs Deal Progress

Profusa, Inc. reported Q2 2026 financial results, highlighting progress on its option agreement to acquire G3 Vision Labs, including debt conversions and a reverse stock split, while facing substantial net losses.

Summary

• Profusa, Inc. announced its financial results for the quarter ended June 30, 2026, and provided an update on its Option Agreement to acquire G3 Vision Labs.
• The company executed a 4:1 reverse stock split effective August 18, 2026, to help meet Nasdaq listing requirements.
• Debt and liabilities holders have executed $10.7 million in Series A Convertible Exchange Agreements, with $4.57 million converted into Series A Convertible Preferred Stock.
• Audited financial statements for G3's 2024 and 2025 financials are expected by mid-September.
• Profusa reported a net loss of $(8.8) million for Q2 2026, compared to $(2.3) million in Q2 2025.
• For the six months ended June 30, 2026, the net loss was $(12.2) million, compared to $(5.1) million for the same period in 2025.
• Cash on hand as of June 30, 2026, was $719,000, with total liabilities at $28.2 million and a total stockholders deficit of $(27.1) million.
• Stockholders equity is expected to be $28.4 million as of July 31, 2026, following the execution of the Option Agreement.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously negative sentiment due to significant financial challenges and ongoing uncertainties surrounding the proposed acquisition, despite some operational progress.

Positives

• Progress made towards satisfying conditions for the Option Agreement to acquire G3 Vision Labs.
• Executed a 4:1 reverse stock split to support Nasdaq minimum listing requirements.
• Secured sufficient working capital for near-term operations through a $650,000 loan.
• Debt and liabilities holders have committed to $10.7 million in convertible exchange agreements, with a significant portion converted to preferred stock.
• G3's auditors are finalizing 2024 and 2025 financial statements, expected by mid-September.
• Stockholders equity is projected to reach $28.4 million by July 31, 2026, post-Option Agreement execution.

Negatives

• Significant net loss of $(8.8) million for Q2 2026, an increase from $(2.3) million in Q2 2025.
• Net loss for the first six months of 2026 was $(12.2) million, more than double the $(5.1) million loss in the prior year.
• Total liabilities stand at $28.2 million as of June 30, 2026.
• A substantial stockholders deficit of $(27.1) million was reported as of June 30, 2026.
• Cash on hand was only $719,000 at the end of Q2 2026, indicating a tight liquidity position.

Risks

• Risks related to Profusa's ability to satisfy all conditions of the Option Agreement.
• Uncertainty regarding the successful integration of G3 Vision Labs and its subsidiaries.
• Potential for customer demand to be less than anticipated.
• Risks associated with the business combination resulting from the option exercise.
• Challenges in complying with representations, warranties, and covenants in the Agreement.
• Risks related to the completion and terms of contemplated financings.
• Possibility that Profusa does not receive necessary stockholder approval.
• Dilutive effect on existing stockholders from the issuance of new shares and preferred stock.

Future Outlook

The company is focused on satisfying the conditions of the Option Agreement to acquire G3 Vision Labs, which is expected to result in a combined public diagnostics company. Audited financials for G3 are anticipated by mid-September. The company has secured near-term working capital.

Management Comments

• "I am very pleased with the timely progress we are making and support we are receiving towards executing the Option to acquire G3," stated Executive Chairman and CEO, Jack Stover.

Industry Context

StockSavvy.ai notes that Profusa's focus on biosensor technologies and digital health aligns with broader industry trends towards personalized medicine and remote patient monitoring. However, the company's current financial state and the significant challenges in closing the G3 acquisition suggest a high-risk profile within this growing sector.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of Series A Convertible Preferred Stock and potential future share issuances.
• Creditors are converting debt into equity, indicating a restructuring of liabilities.
• The successful acquisition of G3 Vision Labs could significantly alter the company's operational focus and market position for all stakeholders.

Next Steps

• Satisfy the conditions of the Option Agreement to acquire G3 Vision Labs.
• Receive audited 2024 and 2025 financial statements for G3 and its subsidiaries by mid-September.
• Continue efforts to meet Nasdaq minimum listing requirements.
• Complete anticipated exchanges of debt and liabilities for equity.

Key Dates

Recommendation

The filing reveals a worsening financial performance with significantly increased net losses and a substantial liabilities burden. While progress is noted on the G3 acquisition and meeting listing requirements, the overall financial health and the inherent risks associated with the acquisition and potential dilution suggest a negative outlook, warranting a sell recommendation.

Keywords

biosensor technologies, digital health, diagnostics, CLIA-certified laboratories, G3 Vision Labs, Option Agreement, convertible preferred stock, reverse stock split